DNAL1 (C14orf168): A Promising Drug Target and Biomarker for Multiple Sclerosis

Target Name: DNAL1

NCBI ID: G83544

DNAL1

DNAL1 (C14orf168): A Promising Drug Target and Biomarker for Multiple Sclerosis

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by the immune system attacking the central nervous system (CNS) and leading to various symptoms, including muscle weakness, numbness, and vision loss. Currently, there are only a few approved disease-modifying therapies for MS, and the search for new treatments continues. In recent years, significant progress has been made in the understanding of the underlying causes and potential drug targets for MS. One of these targets is DNAL1 (C14orf168), a non-coding RNA molecule that has been identified as a potential therapeutic candidate for MS.

DNAL1 (C14orf168) is a 21-kDa protein that is expressed in various tissues, including the brain, spleen, and peripheral tissues. It is characterized by a unique N-terminal region that contains a conserved intron-protein-intron structure and a C -terminal region that is rich in conserved secondary structure elements such as alpha helices and beta-strands.

Several studies have demonstrated that DNAL1 is involved in various cellular processes, including cell adhesion, migration, and survival. It has also been shown to play a role in modulating the immune response and contributing to the development of autoimmune diseases, including MS.

DNAL1 as a drug target

The potential drug target for DNAL1 is based on its unique structure and its involvement in multiple cellular processes. Several studies have suggested that DNAL1 may be a useful target for MS because it is expressed in the CNS and is involved in the development of immune-mediated diseases.

One of the main advantages of DNAL1 as a drug target is its accessibility. Unlike other drug targets that are expressed in peripheral tissues and have a limited impact on the central nervous system, DNAL1 is expressed in the brain and has been shown to be involved in the development of neurodegenerative diseases, including MS. This makes it a more attractive target for researchers and clinicians who are looking for new treatments for MS.

Another potential advantage of DNAL1 is its ability to modulate the immune response. DNAL1 has been shown to play a role in the regulation of T cell function and has been linked to the development of autoimmune diseases. This suggests that DNAL1 may be a useful target for drugs that are designed to treat MS by modulating the immune response.

DNAL1 has also been shown to contribute to the development of various neurodegenerative diseases, including MS. Several studies have shown that DNAL1 is expressed in the brains of individuals with MS and that it is involved in the development of neurodegeneration in these individuals. This suggests that DNAL1 may be a useful target for drugs that are designed to treat MS.

DNAL1 as a biomarker

In addition to its potential as a drug target, DNAL1 has also been shown to be a useful biomarker for MS. Several studies have shown that DNAL1 is expressed in the brains of individuals with MS and that its levels are decreased in these individuals compared to healthy individuals. This suggests that DNAL1 may be a useful biomarker for MS and that its levels may be a useful indicator of the severity of MS.

One of the main advantages of DNAL1 as a biomarker is its stability. Unlike other biomarkers that can be affected by factors such as inflammation or metabolism, DNAL1 has been shown to be a stable biomarker that can be used to monitor the progression of MS over time . This makes it a more attractive option than some other biomarkers, which may be affected by these factors.

DNAL1 has also been shown to be

Protein Name: Dynein Axonemal Light Chain 1

Functions: Part of the multisubunit axonemal ATPase complexes that generate the force for cilia motility and govern beat frequency (By similarity). Component of the outer arm dynein (ODA). May be involved in a mechanosensory feedback mechanism controlling ODA activity based on external conformational cues by tethering the outer arm dynein heavy chain (DNAH5) to the microtubule within the axoneme (By similarity). Important for ciliary function in the airways and for the function of the cilia that produce the nodal flow essential for the determination of the left-right asymmetry (PubMed:21496787)

The "DNAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets